## Clinical Overview Acute Myeloid Leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a clinically aggressive subtype of AML characterized by a poor prognosis and unique biological features. According to the ICD-10-CM classification, the code C92.A0 specifically identifies this condition in patients who have not yet achieved a state of complete remission. This includes patients at the time of initial diagnosis, those currently undergoing induction therapy, and those with refractory disease that has failed to respond to initial treatment protocols. ### Pathophysiology and Classification AML-MRC is defined by the presence of at least 20% myeloid blasts in the bone marrow or peripheral blood, coupled with features that link the leukemia to a pre-existing or underlying myelodysplastic process. These features include: (1) a documented history of a myelodysplastic syndrome (MDS) or a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) that has evolved into AML; (2) the presence of specific MDS-related cytogenetic abnormalities (e.g., complex karyotype, del(5q), monosomy 7); or (3) morphological evidence of multilineage dysplasia (affecting 50% or more of cells in at least two hematopoietic lineages). While the 2022 WHO and ICC classifications have introduced refined terminology (such as 'AML, myelodysplasia-related'), the ICD-10-CM system continues to utilize the C92.A code block to capture these patients. ### Clinical Presentation and Diagnosis Patients typically present with symptoms related to cytopenias, such as severe fatigue (anemia), recurrent or opportunistic infections (neutropenia), and mucosal bleeding or petechiae (thrombocytopenia). Diagnosis requires a comprehensive bone marrow evaluation including morphology, flow cytometry to determine blast lineage, and extensive cytogenetic and molecular testing. Molecularly, AML-MRC often harbors mutations in genes associated with secondary AML, such as ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2. ### Management and Status Specification The designation 'not having achieved remission' is critical for clinical decision-making and resource allocation. For these patients, the standard of care often involves intensive induction chemotherapy—specifically CPX-351, a liposomal formulation of daunorubicin and cytarabine that has shown improved survival in AML-MRC compared to traditional 7+3 regimens. For patients ineligible for intensive therapy, the combination of hypomethylating agents (e.g., azacitidine) and venetoclax is commonly utilized. Achievement of remission is the primary goal to facilitate allogeneic hematopoietic stem cell transplantation (HSCT), which remains the only curative option for this high-risk population.
Distinguish between de novo AML and AML with myelodysplasia-related changes by identifying specific morphologic or cytogenetic markers.
Example: Patient presents with pancytopenia and 22 percent blasts on peripheral smear. Bone marrow biopsy reveals multilineage dysplasia in over 50 percent of cells in two or more myeloid lineages, specifically erythroid and megakaryocytic lines, without prior cytotoxic therapy. Diagnosis: Acute myeloid leukemia with myelodysplasia-related changes, not having achieved remission. Plan: Start induction with liposomal cytarabine and daunorubicin. Comorbidities include chronic kidney disease stage 3a.
Billing Focus: Documentation must specify the presence of multilineage dysplasia or MDS-related cytogenetics to justify C92.A0 over C92.00.
Explicitly state the remission status at every encounter, as the code differentiates between not having achieved remission, in remission, and in complete remission.
Example: 65-year-old male with AML-MRC undergoing day 14 marrow assessment. Results show 12 percent residual blasts with persistent trilineage dysplasia. Condition is acute myeloid leukemia with myelodysplasia-related changes, not having achieved remission. Patient is currently neutropenic with absolute neutrophil count of 0.2 and requires ongoing transfusion support for thrombocytopenia.
Billing Focus: Remission status is the primary axis of classification for the 5th and 6th characters in the C92 series.
Document specific cytogenetic abnormalities such as monosomy 7 or del(5q) that support the myelodysplasia-related changes classification.
Example: Cytogenetic analysis from bone marrow aspirate confirms a complex karyotype including monosomy 7 and deletion of 5q, meeting WHO criteria for AML with myelodysplasia-related changes. Patient remains in active disease state, not having achieved remission. Management involves venetoclax and azacitidine due to fitness for intensive chemotherapy. Secondary diagnosis: Type 2 diabetes with neuropathy.
Billing Focus: Cytogenetic evidence provides the clinical gold standard for assigning the specificity required for C92.A codes.
Capture associated complications such as febrile neutropenia or tumor lysis syndrome within the same clinical note to reflect severity.
Example: Patient admitted for induction therapy for acute myeloid leukemia with myelodysplasia-related changes, not having achieved remission. Currently experiencing febrile neutropenia (temp 102.1F) and suspected tumor lysis syndrome evidenced by rising uric acid (9.2) and phosphorus (5.1). Initiated IV cefepime and rasburicase. Performance status is ECOG 2.
Billing Focus: Coding associated conditions (e.g., D70.1, E88.3) alongside C92.A0 supports medical necessity for high-level E/M codes like 99223 or 99215.
Note a history of a previous Myelodysplastic Syndrome (MDS) if it has progressed to AML, as this defines the myelodysplasia-related changes.
Example: Patient with a 3-year history of Refractory Anemia with Excess Blasts-2 (MDS-EB-2) now demonstrates 25 percent blasts on bone marrow biopsy. The diagnosis is now acute myeloid leukemia with myelodysplasia-related changes (progressed from MDS), not having achieved remission. Patient is also managed for transfusion-acquired iron overload with deferasirox.
Billing Focus: Historical transition from MDS to AML must be documented to support the use of C92.A0 rather than generic AML codes.
Typically used for routine follow-up of AML patients between chemotherapy cycles to monitor blood counts.
Required when managing highly complex cases with multiple comorbidities or life-threatening complications like febrile neutropenia.
Essential for diagnosing AML-MRC and determining remission status by examining cell morphology and blast count.
Crucial for initial screening and monitoring of blast percentage in peripheral blood.
Standard procedure for delivering induction or consolidation therapy for AML-MRC.
Used to identify MDS-related cytogenetic changes such as deletion 5q or 7q, defining the AML-MRC diagnosis.
Used for the initial admission of a patient with new-onset AML-MRC requiring urgent induction therapy.
Frequent procedure for AML patients due to bone marrow failure and treatment-induced cytopenias.
The formal diagnostic procedure to confirm the presence of leukemia and dysplastic changes in the marrow architecture.
Used for stable patients in between cycles or for simple lab checks where clinical complexity is temporarily low.